



ATTORNEY DOCKET NO.: INV#125041

#12  
8-29-03  
PATENT  
[Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jay M. Short  
Application No.: 09/825,852  
Filed: April 3, 2001  
Title: MORPHATIDES: NOVEL SHAPE AND STRUCTURE LIBRARIES

Art Unit: 1639  
Examiner M. Tran

RECEIVED

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AUG 19 2003

TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT**

Sir:

Responsive to the Restriction Requirement mailed June 13, 2003, please consider the following amendments and remarks:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.

Applicant elects with traverse, Group I, Claims 1 and 3-9. Furthermore, regarding a scaffold species elections, Applicant elects, with traverse, a nucleic acid scaffold having a 5' and 3' flanking region with a sequence as set out in SEQ ID NOs:1 and 2 and a randomized middle sequence of 36 nucleotides that includes 3 of the 4 bases occurring at similar frequency and one of the four bases occurring at a rare frequency of 5% (i.e. 2 positions). Regarding a number and type of linker, Applicant elects, with traverse, two identical linkers that are formed by reacting

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on August 13, 2003, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Karen LePari*  
Karen LePari

In re Application of:  
Jay M. Short  
Application No.: 09/825,852  
Filed: April 3, 2001  
Page 2 of 10

PATENT  
Attorney Docket No. INVIT1250-4

phenylboronic acid with salicylhydroxamic acid, each linker being bound to a uridine residue on the scaffold through a 5-position of a uracil base of the uridine residue. Regarding the number and type of agents, Applicant elects, with traverse, two identical nucleic acid agent molecules, each bound to a linker through a 5-position of a uracil base of a uridine residue present on each agent molecule. Regarding a target, Applicant elects, with traverse, a thrombin target. Regarding the type of interaction, Applicant elects, with traverse, a morphatide that binds to, or associates with the agent. Regarding a method for separation, Applicant elects, with traverse, chromatography as a method for separating bound from unbound morphatides.